Neumora Therapeutics, Inc. (NMRA) - Q3 2025 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended September 30, 2025. Neumora Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel therapies for brain and centrally mediated diseases using a precision neuroscience approach. The company has no approved products and has not generated revenue from product sales. Key pipeline assets include navacaprant (Phase 3 for Major Depressive Disorder), NMRA-511 (Phase 1b for agitation in Alzheimer's disease), and various preclinical programs targeting M4 receptors and NLRP3.
Key Financial Metrics
| Metric | Q3 2025 (3 Months) | Q3 2024 (3 Months) | YTD 2025 (9 Months) | YTD 2024 (9 Months) |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Loss | $(56.8) million | $(72.5) million | $(177.5) million | $(185.0) million |
| Diluted EPS | $(0.35) | $(0.45) | $(1.10) | $(1.16) |
| Operating Expenses | $57.7 million | $76.6 million | $182.7 million | $200.5 million |
| Cash & Marketable Securities | $171.5 million (as of Sept 30, 2025) | |||
| Long-Term Debt | $19.6 million (as of Sept 30, 2025) | |||
| Accumulated Deficit | $(1,124.7) million (as of Sept 30, 2025) |
Material Changes vs. Prior Period
- Reduced Operating Expenses: Total operating expenses decreased by $23.9 million (31%) in Q3 2025 compared to Q3 2024. This was driven by a $20.1 million decrease in R&D expenses and a $3.8 million decrease in G&A expenses.
- R&D Efficiency: R&D expenses declined primarily due to reduced manufacturing and clinical trial costs for the navacaprant program ($7.1 million decrease) and the termination of the Amgen Collaboration Agreement in September 2024, which eliminated $12.5 million in related costs for the current quarter.
- Acquired IPR&D: The company recognized $5.0 million in acquired in-process research and development expenses in Q3 2025 related to a Phase 1 development milestone achieved under the Vanderbilt License Agreement. No such expense was recorded in the prior year quarter.
- Debt Financing: In May 2025, the company entered into a loan agreement with K2 HealthVentures LLC. As of September 30, 2025, $20.0 million was drawn, resulting in $0.7 million of interest expense for the quarter. No debt existed in the prior year period.
- Interest Income: Interest income decreased to $1.7 million in Q3 2025 from $4.2 million in Q3 2024, attributable to lower balances in cash equivalents and marketable securities.
Guidance, Outlook, and Risks
- Liquidity Outlook: Management believes existing cash, cash equivalents, and marketable securities ($171.5 million) are sufficient to fund operations for at least the next 12 months. However, the company expects to incur additional losses and will require further capital to complete development and commercialization.
- Subsequent Event (Debt): On November 4, 2025, the company amended its loan agreement with K2 HealthVentures and borrowed an additional $40.0 million ($20.0 million from the remaining first tranche and $20.0 million from the fourth tranche).
- Clinical Updates: The company announced in January 2025 that the KOASTAL-1 study for navacaprant did not demonstrate a statistically significant improvement on the primary endpoint. The company continues to advance other programs, including NMRA-511 and M4 PAMs.
- Legal Proceedings: A putative securities class action lawsuit was filed in February 2025 alleging violations related to the company's 2023 IPO. The company intends to move to dismiss the complaint.
- Risk Factors: Significant risks include the uncertainty of clinical trial outcomes, the need for additional financing, potential dilution from future equity issuances or debt conversion, and contingent consideration obligations from prior acquisitions (BlackThorn, Vanderbilt, Amgen) totaling hundreds of millions of dollars in potential future payments.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $171.5 million cash balance against the burn rate, considering the recent $40 million debt drawdown and ongoing Phase 3 trial costs.
- Debt Covenants: Review the liquidity covenants in the K2 HealthVentures loan agreement, specifically the minimum liquidity requirements effective January 1, 2026 (or July 1, 2026 per amendment), and the conversion rights held by the lender.
- Contingent Liabilities: Assess the potential financial impact of unachieved milestones under the BlackThorn, Vanderbilt, and Amgen agreements, which could require significant cash or equity settlements.
- Clinical Strategy: Evaluate the company's strategic response to the negative primary endpoint results in the navacaprant KOASTAL-1 study and the timeline for subsequent data readouts.
- Legal Exposure: Monitor the status of the securities class action lawsuit filed in February 2025 regarding the IPO.